Telome Health Plans Launch of TeloTest™, a Novel Wellness Biomarker Based on Telomere Length

 Telome Health Plans Launch of TeloTest™, a Novel Wellness Biomarker Based on
                               Telomere Length

Large Clinical Study Supports Prognostic Utility of Saliva-Based TeloTest™

PR Newswire

MENLO PARK, Calif., Nov. 28, 2012

MENLO PARK, Calif., Nov. 28, 2012 /PRNewswire/ --Telome Health, Inc. (THI),
developer of the TeloTest™ diagnostic test that measures average telomere
length, announces the planned launch of the saliva-based TeloTest in the first
quarter of 2013. Related telomere tests, including percentage of short
telomeres, would follow.

Telome Health's TeloTest™ will be the first saliva-based telomere test
available on the market. THI leverages the predictive power of data related to
telomeres, the protective caps at the ends of chromosomes, to help assess
health status, disease and mortality risk, and response to specific therapies.

The utility of testing telomere length in a saliva-based test was recently
reported from an independent, large clinical study sponsored jointly by Kaiser
Permanente, University of California, San Francisco (UCSF), and National
Institutes of Health, in which the average telomere length of 100,000 Kaiser
patients was measured and analyzed relative to other health domains and
clinical outcomes.

In the Kaiser-UCSF study, subjects' medical records were analyzed to confirm
health status over a 2-year period prior to telomere testing. This study
provides an analytical foundation for the prognostic power of the TeloTest.
The study showed that individuals who had short telomeres had increased risk
of death in the three-year follow up period, and that smoking, heavy alcohol
consumption, lower education, and poor environments were associated with short
telomeres, while moderate exercise was associated with longer telomeres. The
mortality risk data remained statistically significant even after accounting
for lifestyle factors. These and other observations are consistent with
earlier studies on blood cell telomere length.

"We knew that telomere length from cells in saliva correlated relatively well
with that in blood cells, but it was important to see that key clinical
associations were also preserved," stated THI's chief scientific officer,
Calvin Harley, Ph.D.

The UCSF team that conducted telomere measurements was led by Dr. Elizabeth
Blackburn, 2009 Nobel Laureate in Physiology and Medicine. The technology used
was qPCR, an extremely well-established technology used in a very broad range
of molecular diagnostic testing, including telomere length. THI licensed the
exclusive, world-wide rights to qPCR-based telomere testing from the
University of Utah in 2010. 

"The strong clinical data and availability of the saliva-based TeloTest will
be the foundation upon which Telome Health's Wellness business will be built.
Because saliva samples can be conveniently collected in a doctor's office or
at home with a non-invasive kit, the saliva-based test provides an important
strategic differentiator from other telomere tests that are currently
available, and is a better test overall due to our qPCR assay technology,
which is scalable, cost-effective and we believe will be the dominant
technology for high-throughput assays," explains Lennart Olsson, M.D., CEO of
Telome Health. "We are actively gearing up for a controlled launch early in
2013 from our clinical laboratory."

"Telomeres are one of the few parts of the genome that can be changed by
lifestyle choices, and hence telomere length measurements can provide valuable
feedback on ones' disease risks and, potentially, the effects of lifestyle
changes," stated Elizabeth Blackburn, Telome Health's Co-founder and Chair of
the Scientific and Clinical Advisory Board. "The data from the saliva-based
testing in the large Kaiser-UCSF research study is an exciting step forward in
the field of telomere science, as it helps to advance the use of telomere
testing into regular clinical practice."

Telome Health's proprietary saliva-based TeloTest™ will provide doctors with
important data about their patients' health and disease risk to better inform
their clinical decisions. In addition to clinical utility, measuring telomere
length will also allow people to gauge their overall health status and
determine whether lifestyle changes are necessary, and potentially indicate
the effectiveness of those changes.

About Telomeres

Over 10,000 peer-reviewed scientific publications relate to telomere biology
and aging or disease and many support the diagnostic utility of telome
measures to monitor health status, disease risk, prognosis, and drug
response. Some of these studies establish both associations and causal links
between short telomeres or altered telomerase levels and major diseases
including cancer, cardiovascular, fibrotic, inflammatory and infectious
diseases, depression, and diabetes. While most biomarkers are specific for
certain diseases, telomere shortness uniquely is a parameter predictive of an
increased risk of many co-morbid diseases and in some studies, it is superior
to conventional biomarkers. Recent data have also suggested that telomere
length may help predict responders, non-responders, or subjects who are at
increased risk for negative side effects of certain drugs.

The multiple applications of telomere-based diagnostics measurement toward
prevention, wellness, and individualized treatment can support a paradigm
shift for healthcare.

About Telome Health, Inc.

Two of THI's founders played key roles in developing the field of telomere
biology: Professor Elizabeth Blackburn, Ph.D. (UCSF), the 2009 Nobel Laureate
in Physiology or Medicine for her seminal work on telomere structure and
function and the discovery of telomerase, the enzyme that synthesizes
telomeric DNA; and Calvin Harley, Ph.D., who linked telomeres and telomerase
to human cell aging and disease, and translated telomere science into drug
development at Geron Corporation as VP Research and Chief Scientific Officer.

There are over 180 million people in the US over age 30 – and a growing number
of them have an interest in actively managing their health. THI founders
believe that telomere length as an overall health barometer will be an
integral component in the personalized medicine revolution, which includes
individualized health maintenance plans based on new health monitoring tools.
As the field of telomere biology continues to evolve, THI will develop and
commercialize additional diagnostics based on telomere biology. The company
currently provides telomere length testing for academic, pharmaceutical, and
corporate research groups.

This news release may contain forward-looking statements made pursuant to the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that statements in this press release regarding
potential applications of THI's technology constitute forward-looking
statements that involve risks and uncertainties, including, without
limitation, risks inherent in the development and commercialization of
potential products, uncertainty of clinical trial results or regulatory
approvals or clearances, need for future capital, dependence upon
collaborators and protection of our intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements.

For more information, contact: Jeanette Smith, 650-289-0289

SOURCE Telome Health, Inc.

Press spacebar to pause and continue. Press esc to stop.